Abstract 913: Differences in basal isoform phosphorylation of signaling proteins between normal and tumor tissue in different cancer types detected by the NanoPro™1000 technologyFlorian T. Unger, Kerstin A. David, Janina Schaller et al.|Cancer Research|2014Cited by 0
Abstract 2408: Comparison of ERK, AKT and MEK isoform phosphorylations between primary and corresponding metastatic colorectal carcinoma lesions using the NanoPro1000 technology.Florian T. Unger, Kerstin A. David, Jana Krueger et al.|Cancer Research|2013Cited by 0
Abstract 3605: Effects of antibody-mediated EGF-receptor inhibition on ERK 1/2 isoform phosphorylation in organoid culturesFlorian T. Unger, Kerstin A. David, Cordula Rosenbrock et al.|Cancer Research|2012Cited by 0
Molecular analysis of drug response in short-term cultivated primary cells of colorectal cancer patientsKevin M. Sullivan, Kerstin A. David, Annika Spruessel et al.|Molecular Cancer Therapeutics|2007Cited by 0
Abstract C228: Preclinical analysis of therapeutic antibody efficiancy using an organoid model-based drug testing platform.Florian T. Unger, Kerstin A. David, Birgit Rabe et al.|Molecular Cancer Therapeutics|2011Cited by 0